Myasthenia gravis is stratified by autoantibody subtype, not severity — only the ~85% of US patients who are AChR-antibody positive are eligible for C5 inhibitors, while MuSK-positive and seronegative patients are excluded from that class.
Myasthenia gravis is an autoantibody-mediated disorder of the neuromuscular junction. Antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK), or LRP4 disrupt signal transmission, producing fluctuating, fatigable weakness. US prevalence is estimated at 100,000–200,000 patients (about 14–20 per 100,000, with recognised underdiagnosis). The population divides by serology: roughly 85% are AChR-antibody positive, about 5% MuSK-antibody positive, around 2% LRP4-positive, and 8–10% seronegative. Because AChR-antibody-mediated disease is complement-driven at the endplate, the C5 inhibitor class is approved only in the AChR-positive subgroup — making serology the commercial and clinical gate, not just a diagnostic label.
Disease severity is defined by the myasthenic crisis: respiratory failure requiring intubation and ICU support. An estimated 15–20% of MG patients experience at least one crisis in their lifetime, with infection the most common precipitant and roughly 4% mortality per episode; historical series show a median of about 13 days to extubation and prolonged intubation predicted by older age and low post-intubation vital capacity. The unresolved clinical and payer question is comparative effectiveness — which patients benefit most from FcRn blockade versus complement inhibition versus traditional immunosuppression remains the outstanding evidence gap.
gMG antibody subtypes — biology, treatment eligibility and commercial implication
| Antibody Subtype | Share of gMG (US est.) | Key Biology | Mechanism Eligibility | Commercial Implication |
|---|---|---|---|---|
| AChR-antibody positive | ~85% | Antibodies to acetylcholine receptor; complement-mediated endplate damage | Eligible for all classes, including C5 inhibitors and FcRn antagonists | Largest segment; the only group the complement class (Soliris, Ultomiris, Zilbrysq) can reach |
| MuSK-antibody positive | ~5% | Antibodies to muscle-specific kinase; often bulbar-predominant, IgG4-driven | FcRn antagonists (rozanolixizumab labelled for MuSK+); not C5 inhibitors | Rituximab-responsive; FcRn is the novel-mechanism option for this subgroup |
| LRP4-antibody positive | ~2% | Antibodies to LRP4; generally milder phenotype | Immunosuppression; FcRn antagonists via broad gMG label | Small subgroup; frequently overlaps the seronegative diagnostic category |
| Seronegative | ~8–10% | No detectable AChR, MuSK or LRP4 antibody on standard assay | FcRn antagonists (no serology restriction); not C5 inhibitors | Diagnostic challenge; captured by the broad FcRn label but excluded from the complement class |
Sources: Gilhus NE. NEJM 2016 (PMID 28029925); Thomas CE et al. Neurology 1997 (PMID 9153452); Myasthenia Gravis Foundation of America; FDA Drugs@FDA (label indications and serology restrictions).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- AChR+ / MuSK+ / LRP4+ / seronegative shares
- the complement-eligible (AChR+) vs FcRn-eligible (all generalised MG) split
- addressable-population sizing per mechanism
Delivers
- Lifetime crisis incidence and mortality
- precipitating factors and predictors of prolonged intubation
- the ocular-vs-generalised and stable-vs-refractory severity axes payers anchor to
Delivers
- Anti-AChR / anti-MuSK serology as the diagnostic anchor
- presenting-symptom patterns (ptosis, diplopia)
- the specialist-referral pathway and the seronegative diagnostic challenge
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why AChR-antibody disease is complement-driven at the endplate, the biological reason C5 inhibitors work only there.
- How MuSK-antibody disease, often bulbar-predominant and IgG4-driven, responds differently than AChR-mediated MG.
- How the 14-20 per 100,000 prevalence estimate translates into 100,000-200,000 diagnosed and undiagnosed US patients.
- Why MGFA epidemiology data still leaves underdiagnosis as the main source of the estimate's wide range.
- Why infection, the most common crisis precipitant, drives roughly 4% mortality per myasthenic-crisis episode.
- How older age and low post-intubation vital capacity predict a longer path to the median 13-day extubation.
- Why the 8-10% of patients with no detectable AChR, MuSK or LRP4 antibody remain the hardest to diagnose confidently.
- How a negative standard-assay result still qualifies a patient for the broad-label FcRn class, not the complement class.
- Why comparative effectiveness across FcRn, complement inhibition and traditional immunosuppression remains the outstanding evidence gap.
- How the ocular-versus-generalised distinction interacts with the stable-versus-refractory axis to define severity tiers.
- Why only the ~85% AChR-positive segment is eligible for Soliris, Ultomiris and Zilbrysq among all four subtypes.
- How MuSK-positive, LRP4-positive and seronegative patients (about 15% combined) route instead to FcRn antagonists.
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Myasthenia Gravis Disease Landscape sources: the Gilhus NE review of myasthenia gravis in the New England Journal of Medicine (pathogenesis, antibody subtypes, diagnosis), the Thomas CE et al. myasthenic-crisis series in Neurology (incidence, mortality, intubation predictors), Myasthenia Gravis Foundation of America epidemiology, and FDA Drugs@FDA labelling for serology-restricted indications.
- Antibody subtype distribution (AChR ~85%, MuSK ~5%, seronegative ~8–10%) verified against Gilhus NE, NEJM 2016 (PMID 28029925)
- Myasthenic crisis incidence, ~4% per-episode mortality, and intubation predictors verified against Thomas CE et al. Neurology 1997 (PMID 9153452)
- C5 inhibitor AChR-antibody-positive label restriction verified against FDA Drugs@FDA
- Prevalence range cross-checked against Myasthenia Gravis Foundation of America estimates
Frequently asked questions
Commission this assessment
AXLRx US Myasthenia Gravis Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the US gMG patient population. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.